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Abstract
Sex steroid hormones, estrogen, progesterone and androgen, play pivotal roles in sex
differentiation and development, and in reproductive functions and sexual behavior. Studies have
shown that sex steroid hormones are the key regulators in the development and progression of
endocrine-related cancers, especially the cancers of the reproductive tissues. The actions of
estrogen, progesterone and androgen are mediated through their cognate intracellular receptor
proteins, the estrogen receptors (ER), the progesterone receptors (PR) and the androgen receptor
(AR), respectively. These receptors are members of the nuclear receptor (NR) superfamily, which
function as transcription factors that regulate their target gene expression. Proper functioning of
these steroid receptors maintains the normal responsiveness of the target tissues to the
stimulations of the steroid hormones. This permits the normal development and function of
reproductive tissues. It can be inferred that factors influencing the expression or function of steroid
receptors will interfere with the normal development and function of the target tissues, and may
induce pathological conditions, including cancers. In addition to the direct contact with the basal
transcription machinery, nuclear receptors enhance or suppress transcription by recruiting an
array of coactivators and corepressors, collectively named coregulators. Therefore, the mutation
or aberrant expression of sex steroid receptor coregulators will affect the normal function of the
sex steroid receptors and hence may participate in the development and progression of the
cancers.
Introduction
The mammary gland, the ovary and the uterus in females,
and the testis and the prostate gland in males are the main
target tissues of sex steroid hormones including estrogen,
progesterone, and androgen. Estrogen is important for the
growth, differentiation and function of both female and
male reproductive tissues [1,2], whereas progesterone is
an essential regulator of the reproductive events associat-
ed with the establishment and maintenance of pregnancy,
including ovulation, uterine and mammary gland devel-
opment [3]. Androgen is involved in the development
and physiological function of male accessory sex organs
[4], and it is also indispensable for the normal develop-
ment and function of female reproductive tissues. These
hormones exert their functions in the target tissues
through their specific intracellular receptors, the estrogen
receptors (ER), the progesterone receptors (PR) and the
androgen receptor (AR), which belong to the nuclear re-
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ceptor (NR) superfamily and function as transcription fac-
tors to regulate the target gene expression [5]. The
abnormal expression or function of these receptors has
been implicated in tumors of reproductive organs in both
genders. Furthermore, the development of resistance to
hormonal replacement therapy for either breast or pros-
tate cancers is also related to aberrant expression, muta-
tion of the genes and abnormal functioning of the
respective steroid receptors.
As members of the NR superfamily, the sex steroid recep-
tors, ER, PR and AR, share the characteristic structure with
other nuclear receptors (NRs): an amino-terminal activa-
tion, AF-1 (A/B domain); the DNA-binding domain
(DBD) (C); a hinge region (D domain); and a carboxy-ter-
minal ligand-binding domain (LBD) (E), which contains
a second activation function, AF-2 [5]. In the absence of
hormones, NR is sequestered in a non-productive form as-
sociated with heat shock proteins and other cellular chap-
erones. In this state, NR is inactive and unable to influence
the transcription rate of its target gene promoters [5,6].
Upon binding with the cognate hormones, the receptors
undergo a series of events, including conformational
changes, dissociation from heat shock protein complexes,
dimerization, phosphorylation, and nuclear transloca-
tion, which enables their binding to hormone-response
elements (HREs) within the regulatory regions of target
genes [5,6]. The binding of hormones to the HREs causes
the recruitment of coactivators and basal transcription
machinery, leading to the upregulation of target gene
transcription.
Coactivators are factors that can interact with NRs in a lig-
and-dependent manner and enhance their transcriptional
activity. Corepressors are factors that interact with NRs, ei-
ther in the absence of hormone or in the presence of anti-
hormone, and repress their transcriptional activity. Both
types of coregulators are required for efficient modulation
of target gene transcription by steroid hormones. There-
fore, changes in the expression level and pattern of steroid
receptor coactivators or corepressors, or mutations of their
functional domains can affect the transcriptional activity
of the steroid hormones and hence cause disorders of
their target tissues. This review will summarize our current
understanding about the roles that the coactivators and
corepressors may play in the development and progres-
sion of cancers in both male and female reproductive tis-
sues.
The SRC family
The SRC (steroid receptor coactivator) family is composed
of three distinct but structurally and functionally related
members, which are named SRC-1 (NcoA-1), SRC-2
(TIF2/GRIP1/NcoA-2), and SRC-3 (p/CIP/RAC3/ACTR/
AIB1/TRAM-1), respectively [5]. Sequence analysis of SRC
proteins identified a basic helix-loop-helix (bHLH) do-
main and two Per-Arnt-Sim (PAS) domains in the amino-
terminal region, a centrally located receptor-interacting
domain (RID) and a C-terminal transcriptional activation
domain (AD). The bHLH/PAS domain is highly conserved
among the SRC members and it serves as a DNA binding
and protein dimerization motif in many transcription fac-
tors. Detailed analysis revealed three conserved LXXLL
motifs (NR box) in the RID, which appear to contribute to
the specificity of coactivator-receptor interaction. Histone
acetyltransferase (HAT) activity was identified in the C-
terminal region of SRC members and there also exist acti-
vation domains that can interact with the CREB-binding
protein (CBP). The members of the SRC family interact
with steroid receptors, ER, PR and AR, and enhance their
transcriptional activation in a ligand-dependent manner
[5].
SRC-1 was the first coactivator for the steroid receptor su-
perfamily that was cloned and characterized [7]. SRC-1 is
a common transcription mediator for nuclear receptors,
functioning through its HAT activity and multiple interac-
tions with agonist-bound receptors. SRC-1 exhibits a
broad range of specificity in the coactivation of the hor-
mone-dependent transactivation of nuclear receptors, in-
cluding PR, ER, GR (glucocorticoid receptor), TR (thyroid
hormone receptor), and AR. Targeted deletion of SRC-1
gene in mice has indicated that SRC-1 is required for effi-
cient steroid hormone action in vivo; for estrogen and
progesterone action in the uterus and mammary gland,
and for androgen action in the prostate and testis [8].
The role of SRC-1 in the development or progression of
cancers is not clear. Although it is an important coactiva-
tor for ER and PR, there have been no positive results
showing that the expression of SRC-1 is altered in breast
cancers or ovarian cancers. However, results from differ-
ent groups indicated that SRC-1 is involved in the progres-
sion of prostate cancers. Using RT-PCR (reverse
transcriptase-polymerase chain reaction), Fujimoto and
colleagues found that the expression levels of SRC-1 were
higher in higher grade prostate cancers or cancers with a
poor response to endocrine therapy [9]. At the same time,
Gregory et al reported that SRC-1 expression was elevated,
together with the expression of AR, in recurrent prostate
cancers [10]. Gregory et al found that SRC-2 is also over-
expressed in recurrent prostate cancers. Overexpression of
SRC-1 and SRC-2 confers on AR an increased sensitivity to
the growth-stimulating effects of low androgen concentra-
tions. This change may contribute to prostate cancer recur-
rence after androgen deprivation therapy.
SRC-3 is the most distinct among the three members of
SRC family; it coactivates not only the nuclear receptors
but also other unrelated transcription factors such asMolecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/7
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those in the cAMP or cytokine pathways. Compared with
the widespread expression of SRC-1 and SRC-2, expres-
sion of SRC-3 is restricted to few tissues, including the
uterus, the mammary gland and the testis [11]. Disruption
of SRC-3 gene in mice causes severe growth and reproduc-
tive defects, such as the retardation of mammary gland de-
velopment [12]. Amplification and overexpression of
SRC-3 in human breast and ovarian cancers have been ob-
served [13–17]. Bautista et al reported that the AIB1 (SRC-
3) amplification/overexpression was correlated with ER
and PR positivity [14]. However, Bouras et al found that
SRC-3 had an inverse correlation with steroid receptors,
but a positive correlation with HER-2/Neu and p53 ex-
pression [17]. Despite of the conflicting results, the over-
expression of SRC-3 in breast and ovarian tumors
indicates that SRC-3 is an important factor in the tumori-
genesis of the mammary gland and ovary. There is no clear
evidence about the possible roles of SRC-3 in prostate tu-
mor development and progression.
SRA/SRAP
The steroid receptor RNA activator (SRA) is a unique coac-
tivator for steroid receptors, PR, ER, GR, and AR. Differing
from the other coactivators, SRA was found to function as
a RNA transcript instead of as a protein [18]. Besides, SRA
existed in a ribonucleoprotein complex containing SRC-1
and it mediated transactivation through the AF-1 domain
located at the N-terminal region of nuclear receptors, dis-
tinguishing it from the other coactivators [18].
SRA is expressed in normal and malignant human mam-
mary tissues [15,19]. Compared with the adjacent normal
region, elevated expression of SRA was found in breast tu-
mors [15]. Although it is currently unknown whether the
expression of SRA is correlated with that of PR or ER, the
increase in the SRA levels in tumor cells may contribute to
the altered ER/PR action, which is known to occur during
breast tumorigenesis.
Recently, Kawashima et al reported the cloning and char-
acterization of a novel steroid receptor coactivator from a
rat prostate library [20]. The nucleotide sequence of this
coactivator has 78.2% identity to that of human SRA,
however, the cDNA of this coactivator can be transcribed
into a functional protein and exerts its coactivation func-
tion as a protein instead of an RNA transcript [20]. There-
fore, it was designated as steroid receptor activator
protein, SRAP. Kawashima et al demonstrated that SRAP
could enhance the transactivation activity of AR and GR in
a ligand-dependent manner. The mRNA of SRAP was ex-
pressed in all the rat prostate cancer cell lines examined,
while that of SRA was expressed in all the human prostate
cancer cell lines. The expression level of SRA is higher in
androgen-independent PC-3 cells compared with that of
the androgen-dependent cell lines, DU-145 and LNCaP.
Taken together, these results suggested that both SRA and
SRAP play an important role in NR-mediated transcrip-
tion in prostate cancer.
E6-AP/RPF1
E6-associated protein, E6-AP, and RPF1, the human ho-
molog of yeast RSP5, are E3 ubiquitin-protein ligases that
target proteins for degradation by the ubiquitin pathway.
They are also characterized as coactivators of steroid re-
ceptors. It has been demonstrated by transient transfec-
tion assay that RPF1 and E6AP can potentiate the ligand-
dependent transcriptional activity of PR, ER, AR, GR, and
other NRs [21,22]. Furthermore, they also act synergisti-
cally to enhance the transactivation of NRs [22]. Addition-
ally, the coactivation functions of E6-AP and RPF1 are not
dependent on the E3 ubiquitin-protein ligase activity.
E6-AP is expressed in many tissues including the uterus,
ovary, testis, prostate and mammary gland. It is important
in the development and function of these tissues, since
E6-AP null mutant mice exhibited defects in reproduction
in both male and female mice [23].
The first evidence of a relationship between E6-AP and
cancer was obtained from the study of a spontaneous
mouse mammary tumorigenesis model. In this spontane-
ous model, E6-AP was overexpressed in mammary tumors
when compared with normal tissues [24]. Recently, we ex-
amined the expression pattern of E6-AP in biopsy samples
of human breast cancers. Our results showed that E6-AP
expression was decreased in tumors in comparison to the
adjacent normal tissues (Gao et al, unpublished data). In
addition, the expression of E6-AP was inversely correlated
with that of ER in breast tumors, and the decreased expres-
sion of E6-AP was stage-dependent. Interestingly, the de-
creased expression of E6-AP was also found in human
prostate cancers (Gao et al, unpublished data). ER plays a
major role in breast cancer development, and PR is also a
target of estrogen. Thus, changes in the expression level of
E6-AP, a coactivator for ER and PR, might interfere with
the normal functioning of ER and PR, hence participating
in the formation and progression of breast tumors. In a
similar way, the altered expression of E6-AP might influ-
ence the normal functioning of AR, which plays a major
role in the progression of prostate cancers.
ASC-2/TRBP/AIB3
ASC-2 (the nuclear protein-activating signal cointegrator-
2), also called AIB3 (the amplified in breast cancer 3) and
TRBP (TR-binding protein), has recently been character-
ized as a NR coactivator [25]. ASC-2 interacted with NRs,
such as retinoid acid receptor (RAR), TR, ER, and GR, and
stimulated the ligand-dependent and AF2-dependent
transactivation of the NRs either alone or in conjunction
with CREB-binding protein (CBP)/p300 and SRC-1. Sub-Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/7
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sequent study showed that ASC-2 also interacted with SRF
(the serum response factor), AP-1 (the activating protein-
1), NF-κB (the nuclear factor-κB), and potentiated trans-
activation by these mitogenic transcription factors [26].
This suggests that ASC-2 is a multifunctional transcription
integrator molecule.
ASC-2 is likely involved in the tumorigenesis of mammary
gland, because it is amplified and overexpressed in hu-
man breast cancer specimens as well as in all the human
breast cancer cell lines examined. Moreover, it may also
regulate cellular proliferation or tumorigenesis by the di-
rect interaction with SRF, AP-1 and NFκB.
L7/SPA
L7/SPA, L7/switch protein for antagonists, is a 27 kDa
protein containing a basic leucine zipper domain. L7/SPA
is an antagonist specific transcriptional coactivator be-
cause it can only potentiate the partial agonist activity of
some antagonists, including tamoxifen and RU486, but
has no effect on the agonist-mediated transcription [27].
The study by Graham et al indicated that the relative levels
of the coactivator, L7/SPA, vs. the corepressors, which
suppress the partial agonist activity of tamoxifen or
RU486, might determine whether the agonist or antago-
nist effects of these mixed antagonists predominate in a
tissue or tumor [28]. This unique property of L7/SPA
could partially explain the development of resistance to
hormone therapy for breast cancers.
ARAs
ARAs, androgen receptor-associated proteins, is a group of
factors that can bind to AR and modulate its transcription-
al activity. Based on their molecular weights, these factors
were named ARA70, ARA160, ARA54, ARA55, ARA267
and ARA24.
ARA70, which has a molecular weight of 70-kDa, is also
named as RFG (RET fused gene) and ELE1. ARA70 was
first described as an AR-specific coactivator by Chang's
group in 1996 [29]. In that report, ARA70 was demon-
strated as a factor, which specifically interacts with AR and
enhances the transcriptional activity of AR in response to
the stimulation of androgens, including testosterone and
dihydrotestosterone, but not the antiandrogen, hy-
droflutamide (HF). Later, it was reported that ARA70
could also interact with and facilitate the agonist activity
of antiandrogens, including cyproterone (CPA), HF, and
bicalutamide (casodex) [30]. Recent studies by other
groups showed that ARA70 was not a specific coactivator
for AR; it could also interact with PR or GR [31,32]. How-
ever, studies on the expression patterns of ARA70 in dif-
ferent cell lines and human cancer samples showed that
the expression of ARA70 was decreased in prostate cancer
[31,33–35] and breast cancer, [36] while it was increased
in ovarian cancers. In breast, loss of ARA70 protein expres-
sion was found in 60% of HER2 positive breast cancers,
while only 33% of HER2 negative breast cancer samples
lost the expression [36]. Since androgen plays an inhibito-
ry role for breast cancer cell growth, and HER2 stimulates
the growth of breast cancers, loss of the expression of AR
and/or ARA70 in breast might confer a growth advantage
to these cells. In prostate, ARA70 mRNA is highly ex-
pressed in the normal epithelial cells, while benign pros-
tatic hyperplasic and cancer cell lines express either lower
or no ARA70 [36]. Methylation might be responsible for
the lack of expression of ARA70 in some prostate cancer
cells such as DU145 [36]. The expression of ARA70 in
prostate cancer cells seems to be regulated by both ER and
AR, since the prostate cancer cell line, PC-3, responded to
estrogen/androgen and their respective antagonists differ-
ently in the parental PC-3 cells (AR-negative) and its de-
rived AR-positive cells.
Other members of the ARA group, such as ARA54, ARA55,
ARA24, ARA160, and ARA267 were also implicated in
prostate tumors [35,37–40]. The expression of these coac-
tivators was more or less altered in human prostate cancer
cell lines or biopsy samples. However, the exact roles of
these factors in prostate tumorigenesis need to be deter-
mined.
The PIAS family
The PIAS (protein inhibitor of activated signal transducer
and activator of transcription) family is composed of a
group of proteins that share a high sequence homology
[41]. The first member of this family, PIAS1, was charac-
terized as a coactivator for AR [42]. Through its N-termi-
nal LXXLL motifs, PIAS1 interacted with and coactivated
the AR transcriptional activity in a ligand-dependent man-
ner [42]. Besides, PIAS1 could also modulate the activities
of steroid receptors such as GR, PR and ER [42,43]. PIAS1
was expressed predominantly in the testis [42]. Further-
more, overexpression of PIAS1 was found in 33% of the
prostate cancer samples examined [35]. These data sug-
gested a possible role that PIAS1 may play in normal or
cancer development of the testis or prostate.
Another important member of the PIAS family is called
PIASxα or ARIP3 (AR-interacting protein 3). PIASxα/
ARIP3 is similar to PIAS1 in that it is also expressed pre-
dominantly in the testis, and functions as a coactivator for
AR [43,44].
SNURF
The small nuclear RING finger protein, SNURF, was iden-
tified in a yeast two-hybrid screening using the DBD of AR
as a bait [45]. SNURF interacted with AR, GR and PR, and
enhanced their transcriptional activity in a ligand-de-
pendent fashion. It also potentiated the basal transcrip-Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/7
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tion from steroid-regulated promoters [45]. SNURF is a
nuclear protein. The expression of SNURF was relatively
high in the brain, but low in the testis, prostate, seminal
vesicles, spleen and kidney [45]. Moreover, the nuclear lo-
calization signal (NLS) in SNURF was found to be able to
facilitate the nuclear import and export of AR [46], which
is important for normal functioning of AR transactivation.
BRCA1
BRCA1 is a breast cancer susceptibility gene, and its inher-
ited mutations are correlated with an increased risk of
breast and ovarian cancers [47]. The role of BRCA1 in can-
cer development is quite complex. On one hand, BRCA1
was shown to coactivate p53, modulate p300/CBP expres-
sion, and function as a ligand-independent corepressor
for ER, PR, and AR [48–50]; on the other hand, it was
shown that it could enhance the ligand-dependent AR
transactivation in both breast and prostate cancer cell
lines, especially in the presence of exogenous SRC family
members [51]. These results are somewhat controversial
regarding the influence of BRCA1 on AR activity. ER and
PR play key roles in breast cancer development and pro-
gression, and AR signaling in the breast has protective ef-
fect. Thus, it is reasonable to speculate that the normal
expression of BRCA1 probably protect the breast from tu-
morigenesis by suppressing the ER and PR signaling path-
way and promoting the AR activity. Mutation of the
BRCA1 gene, therefore, increases the risk of developing
cancer.
In a recent study by Ko et al. a genomic transcript, GT198,
that mapped to the human breast cancer susceptibility lo-
cus (17q12-q21), was characterized as a coactivator for
nuclear receptors such as AR, ER, PR, GR, etc [52]. GT198
has a tissue-specific expression pattern; it is expressed
highly in testis, moderately in thymus, spleen, and pitui-
tary, and hardly detected in other tissues. The role of this
novel coactivator in cancers of testis or breast needs to be
explored.
CBP/p300
CREB-binding protein (CBP) was initially characterized as
a coactivator required for efficient transactivation of
cAMP-response element-binding protein. p300 was first
identified as a coactivator of the adenovirus E1A oncopro-
tein. CBP and p300 share many functional properties.
Both of them function as coactivators for multiple NRs as
well as p53 and NF-kB; both possess intrinsic HAT activity
and both can recruit HAT and p/CAF (CBP/p300-associat-
ed factor) [5]. Besides, CBP/p300 interacts with members
of SRC family and synergizes with SRC-1 in the transacti-
vation of ER and PR [53]. Based on its wide expression
and multiple functions, it is speculated that CBP/p300
might participate in the process of tumor initiation and
progression.
N-CoR/SMRT
N-CoR and SMRT are both corepressors of numerous tran-
scription factors, including steroid hormone receptors.
Both N-CoR and SMRT interact with the nuclear receptors
through the RIDs located in the C-terminal portion of the
proteins, while their transcriptional repression domains
were mapped to the N-termini [54]. N-CoR/SMRT also as-
sociates with HDAC3 (histone deacetylase 3) in large pro-
tein complexes, which is an important pathway for
transcriptional repression. Corepressors N-CoR and SMRT
interact with the NRs either in the absence of agonists (in
the case of TR and RAR), or in the presence of antagonists
(in the case of steroid receptors) [54]. As mentioned
above, corepressors, N-CoR and SMRT, can suppress the
partial agonist activity of antagonists, counteracting the
effects of L7/SPA. The alteration of the expression of these
corepressors changes the balance of corepressors to coac-
tivators that are bound to the transcription complex via
the antagonist-occupied steroid receptors. This might de-
termine whether the outcome is inhibitory or stimulatory,
and therefore determine whether tamoxifen-resistance
will occur or not.
Other coregulators
In addition to the above-mentioned coactivators and
corepressors, there are many other factors that have been
characterized as sex steroid receptor coregulators. These
include HMG-1/2 (the chromatin high-mobility group
protein-1, 2), TIP60 (Tat-interacting protein), PNRC1/2
(proline-rich nuclear receptor coregulatory protein-1, 2),
Cdc25B, Uba3 (ubiquitin-activating enzyme 3), and RTA
(repressor of tamoxifen transcriptional activity) [55–60].
At present, it is not clear whether these coregulators are in-
volved in the development of cancers.
Conclusion
Steroid receptors activate their target gene transcription in
response to the hormonal stimulus. Their transactivation
activities are modulated by coregulators (coactivators and
corepressors). Different coregulators exert their actions
through different mechanisms. Involvement of coregula-
tors in the development and progression of cancers is
complex. Most of the steroid receptor coactivators and
corepressors identified so far are widely expressed. They
usually can modulate the transactivation of multiple re-
ceptors. On the other hand, the transactivation function
of a single nuclear receptor in certain tissues is usually reg-
ulated by multiple coregulators. Much evidence supports
the importance of coregulators in tumorigensis and the
development of hormone-resistance in breast or prostate
cancers. The understanding of the mechanisms of the ac-
tions of these coregulators will be helpful for the develop-
ment of new cancer therapies.Molecular Cancer 2002, 1 http://www.molecular-cancer.com/content/1/1/7
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